Table 5.

Description of overall cardiovascular toxicity observed with pazopanib treatment

Entire Study Population (n)	35
Any CV toxicity	24 (69%)
Any CV toxicity excluding hypertension	12 (34%)
Grade 1 QTc prolongation	6 (17%)
Grade 2 QTc prolongation	2 (6%)
Grade 3 heart failure	1 (3%)
Grade 5 heart failure	1 (3%)
Grade 3 atrial flutter	1 (3%)
Grade 3 peripheral ischemia	1 (3%)
Grade 2 hypertension	3 (9%)
Grade 3 hypertension	17 (49%)

n number, CV cardiovascular, QTc corrected QT interval. Refer to Table 1 for grading definitions. Results displayed as number of patients (% of all study patients)